ArticleCancer medicine2024

Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Feng Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.